Association between GLP-1-based therapy and small-bowel transit time during capsule endoscopy: a prospective, multicentre, observational study - Report - MDSpire
Advertisement
Association between GLP-1-based therapy and small-bowel transit time during capsule endoscopy: a prospective, multicentre, observational study
Clinical Report: Relationship of GLP-1 Therapy with Small-Bowel Transit Duration
Overview
This study evaluates the impact of GLP-1-based therapy on small-bowel transit time during capsule endoscopy. Findings indicate that patients on GLP-1 therapy have significantly longer small-bowel transit times compared to controls, although other outcomes such as gastric transit time and capsule completion did not show significant differences.
Background
GLP-1 receptor agonists are increasingly used for managing type 2 diabetes and obesity, and their effects on gastrointestinal motility are clinically relevant, particularly during endoscopic procedures. Understanding the impact of these therapies on small-bowel transit is crucial for optimizing capsule endoscopy outcomes.
Data Highlights
Outcome
GLP-1 Therapy
Control
P-value
Small-bowel transit time (min)
311.0 (IQR 252.8–433.0)
236.0 (188.0–282.5)
<0.001
Gastric transit time (min)
33.5 (15.2–51.8)
22.5 (11.0–42.5)
0.263
Capsule completion (%)
91.2%
98.9%
0.056
Repeat examination recommendation (%)
11.8%
3.2%
0.078
Clinically significant findings (%)
23.5%
34.7%
0.322
Key Findings
Patients on GLP-1 therapy had longer unadjusted small-bowel transit times compared to controls (311.0 vs 236.0 min; p<0.001).
No significant difference in gastric transit time was observed between groups (33.5 vs 22.5 min; p=0.263).
Capsule completion rates were numerically lower in the GLP-1 group (91.2% vs 98.9%; p=0.056).
Recommendations for repeat capsule examinations were higher in the GLP-1 group (11.8% vs 3.2%; p=0.078).
Clinically significant endoscopic findings did not differ significantly between groups (23.5% vs 34.7%; p=0.322).
GLP-1 therapy was independently associated with longer small-bowel transit time after multivariable adjustment (adjusted β+83 min; p=0.042).
Clinical Implications
The findings indicate that GLP-1-based therapy is associated with longer small-bowel transit times.
Conclusion
GLP-1-based therapy is linked to prolonged small-bowel transit time during capsule endoscopy.
